Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT800 with or without daratumumab for immune tolerance induction in hemophilia A with high-titer inhibitors
ChiCTR2200067033Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in hemophilia A comparing SCT800 + daratumumab with SCT800 monotherapy (2 arms). Primary endpoints: success rate of ITI and success rate and partial success rate of ITI after 3 months of treatment. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
omfiloctocog alfadaratumumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on ChiCTR2200067033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067033.